EUCTR2015-005352-10-Outside-EU/EEA进行中（未招募）不适用
Immunogenicity and Safety of the Aventis Pasteur DTacP-IPV//PRP~T Combined Vaccine (PENTAXIM™) Given as a Three-Dose Primary Vaccination at 2, 4 and 6 Months of Age and Followed by a Booster Dose at 18 to 19 Months of Age in Healthy Infants in Thailand. All Infants Receiving Recombinant Hepatitis B Vaccine at 0, 2 and 6 Months of Age.
SANOFI PASTEUR INTERNATIONA0 个研究点目标入组 186 人开始时间: 2015年12月4日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 186
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1) Aged 53 to 70 days inclusive on the day of inclusion
- •2) Born at full term pregnancy (>37 weeks) with a birth weight = 2.5 kg
- •3) Informed consent form signed by the parent(s) or other legal representative
- •4) Able to attend all scheduled visits and to comply with all trial procedures
- •5) First dose of Hepatitis B vaccine received within 24 hours of birth
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 186
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1) Participation in another clinical trial in the 4 weeks preceding the (first) trial vaccination
- •2) Planned participation in another clinical trial during the present trial period
- •3) Congenital or acquired immunodeficiency, immunosuppressive therapy such as long-term systemic corticosteroids therapy
- •4) Systemic hypersensitivity to any of the vaccine components or history of a life threatening reaction to the trial vaccine or a vaccine containing the same substances
- •5) Chronic illness at a stage that could interfere with trial conduct or completion.
- •6) Blood or blood–derived products received in the past.
- •7) Mother known as seropositive to HIV or Hepatitis B
- •8) Any vaccination in the 5 weeks preceding the first trial vaccination (except BCG)
- •9) History of diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type b infection or Hepatitis B (confirmed either clinically, serologically or microbiologically).
- •10) Previous vaccination against the diphtheria, tetanus, pertussis, poliomyelitis diseases or Haemophilus influenzae type b infection with the trial vaccine or another vaccine.
- •11) Thrombocytopenia or a bleeding disorder contraindicating intramuscular vaccination
- •12) History of/current seizures
- •13) Febrile illness (rectal temperature = 38.0°C or axillary temperature = 37.4°C) or acute illness on the day of inclusion.
研究者
相似试验
进行中（未招募）
不适用
Immunogenicity and Safety of Pentaxim in South African Infants.Healty volunteers: active immunization against diphtheria, tetanus, pertussis, poliomyelitis and invasive infections caused by Haemophilus influenzae type b (such as meningitis, septicaemia, cellulitis, arthritis, epiglottitis, pneumopathy, osteomyelitis).MedDRA version: 18.1Level: LLTClassification code 10036897Term: Prophylactic vaccinationSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 18.1Level: HLGTClassification code 10043413Term: Therapeutic procedures and supportive care NECSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 18.1Level: PTClassification code 10021430Term: ImmunisationSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 18.1Level: HLTClassification code 10021431Term: ImmunisationsSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2015-005354-35-Outside-EU/EEASANOFI PASTEUR INTERNATIONA212
招募中
3 期
Study of DTaP-IPV-Hep B-PRP-T Combined Vaccine in Indian Infants Previously Given a Dose of Hepatitis B Vaccine at BirthCTRI/2013/09/003997Sanofi Pasteur SA177
进行中（未招募）
1 期
Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine in Indian Infants Previously Given a Dose of Hepatitis B Vaccine at BirthPrevention of infections caused by Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis, poliovirus type 1, 2 and 3, prevention against invasive infections caused by Haemophilus influenzae type b and infection caused by hepatitis B virusEUCTR2016-002089-29-Outside-EU/EEASanofi Pasteur SA177
进行中（未招募）
1 期
DTaP-IPV-Hep B-PRP~T Combined Vaccine versus DTaP-IPV//PRP~T Combined Vaccine + Hep B Vaccine in Hep B Primed InfantsDiphtheria, Tetanus, Pertussis, Haemophilus Influenzae Type b infection, Poliomyelitis, and Hepatitis BEUCTR2016-002873-36-Outside-EU/EEASanofi Pasteur SA310
进行中（未招募）
不适用
Immunogenicity and Safety of TETRAXIM™ Given as a Booster Dose at 4 to 6 Years of Age.Healthy volunteers: indicated for primary vaccination in infants for active immunization against diphtheria, tetanus, pertussis and poliomyelitis.MedDRA version: 18.1Level: LLTClassification code 10036897Term: Prophylactic vaccinationSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 18.1Level: HLGTClassification code 10043413Term: Therapeutic procedures and supportive care NECSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 18.1Level: PTClassification code 10021430Term: ImmunisationSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 18.1Level: HLTClassification code 10021431Term: ImmunisationsSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2015-005403-87-Outside-EU/EEASANOFI PASTEUR SA167